Generate a tailored SOP for Dr. David Miklos. Improve your application with a focused, well-structured draft.
David Miklos is a Professor in the Department of Medicine at Stanford University, specializing in Blood and Marrow Transplantation. He leads the Stanford BMT Cell Therapy Program, which provides around 750 cancer cell therapies annually. His research primarily focuses on allogeneic hematopoietic cell transplantation (alloHCT) and CAR-T cell therapy. He has pioneered studies optimizing graft content for improved treatment outcomes in blood cancers, investing extensively in both laboratory and clinical research. His lab is known for advancing protein microarray technologies aimed at identifying clinically relevant allogeneic antibodies. Miklos has significantly contributed to the understanding of chronic graft-versus-host disease (cGVHD) therapeutic strategies, including his work on the use of anti-B cell drugs in clinical trials. He has received various prestigious awards, including Phi Beta Kappa from the University of Notre Dame and Alpha Omega Alpha from Yale Medical School. His academic journey includes degrees in Genetics and Medicine from Yale University. David has authored numerous publications and is an influential figure in the field of cancer immunotherapy, continuously evaluating the efficacy of innovative CAR-T therapies at Stanford University.
Stanford University • Stanford, California
Overseeing the BMT Cell Therapy Program, leading clinical research initiatives.
Stanford University • Stanford, California
Coordinating clinical operations and research activities.
Stanford University • Stanford, California
Directed clinical programs focusing on innovative cancer therapies.
Stanford University • Stanford, California
Managed laboratory initiatives for transplantation therapies.
The Computer Science department emphasizes research potential. GRE General is currently optional but recommended for some tracks.